The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Abbvie; Janssen; Karyopharm Therapeutics; Kite/Gilead; MorphoSys; Novartis; TeneoBio
Speakers' Bureau - AstraZeneca; BeiGene; Epizyme; MorphoSys
Research Funding - Merck (Inst); Merck (Inst)
Promising tolerability and efficacy results from dose-escalation in an ongoing phase Ib/II study of mosunetuzumab (M) with polatuzumab vedotin (Pola) in patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (B-NHL).
 
L Elizabeth Budde
Honoraria - AstraZeneca
Consulting or Advisory Role - Kite/Gilead; Novartis; Roche/Genentech
Speakers' Bureau - AstraZeneca; Kite, a Gilead company
Research Funding - Amgen; AstraZeneca; Merck; MustangBio
Patents, Royalties, Other Intellectual Property - CCR4 CAR T cells for treatment of patients with CCR4 positive cancer.; CD33CAR for treatment of patients with CD33+ acute myeloid leukemia.
Travel, Accommodations, Expenses - AstraZeneca; Kite/Gilead; Roche/Genentech
 
Nilanjan Ghosh
Consulting or Advisory Role - Adaptive Biotechnologies; AstraZeneca; Beigene; Bristol-Myers Squibb; Genmab; Gilead Sciences; Karyopharm Therapeutics; Pharmacyclics/Janssen; Seagen; TG Therapeutics; Verastem
Speakers' Bureau - Abbvie; AstraZeneca; Bristol-Myers Squibb; Celgene; Epizyme; Janssen Oncology; Kite/Gilead; Pharmacyclics/Janssen; Seagen
Research Funding - Forty Seven (Inst); Genentech/Roche (Inst); Juno Therapeutics (Inst); Pharmacyclics (Inst); Seagen (Inst); TG Therapeutics (Inst)
 
Julio C. Chavez
No Relationships to Disclose
 
Izidore S. Lossos
Honoraria - Janssen Biotech
Consulting or Advisory Role - Janssen Scientific Affairs; Seagen; Verastem
Research Funding - NCI
Patents, Royalties, Other Intellectual Property - Stanford- Royalties
 
Amitkumar Mehta
Stock and Other Ownership Interests - Witty Health
Consulting or Advisory Role - Aileron Therapeutics; AstraZeneca; Bristol-Myers Squibb; Carevive; Incyte; Kite, a Gilead company; Kyowa Kirin International; Pharmacyclics; Rigel; Seagen; Spectrum Pharmaceuticals; TG Therapeutics
Speakers' Bureau - AstraZeneca; Gilead Sciences; Incyte; Kite, a Gilead company; Seagen; Spectrum Pharmaceuticals
Research Funding - ADC Therapeutics; ADC Therapeutics (Inst); Affimed Therapeutics; Aileron Therapeutics (Inst); Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Carevive (Inst); Epizyme (Inst); Forty Seven (Inst); Gilead Sciences (Inst); incyte (Inst); Innate Pharma; Juno Therapeutics (Inst); Merck (Inst); oncotartis (Inst); Pharmacyclics/Janssen (Inst); Rhizen Pharmaceuticals; Roche/Genentech (Inst); Seagen (Inst); Takeda (Inst); TG Therapeutics
 
Kathleen Anne Dorritie
Honoraria - Onc Live
Research Funding - Genentech/Roche; Genmab/Seattle Genetics; Janssen Research & Development; Juno Therapeutics; Kite, a Gilead company; Nordic Nanovector
Travel, Accommodations, Expenses - Kite, a Gilead company; Nordic Nanovector
 
Manali K. Kamdar
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; AstraZeneca; BeiGene; Celgene; Karyopharm Therapeutics; Pharmacyclics/Janssen
Speakers' Bureau - Seagen
Research Funding - TG Therapeutics (Inst)
 
Raluca Negricea
Employment - Roche
 
Song Pham
Employment - Roche
 
Maria Hristopoulos
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche/Genentech
 
Ling-Yuh Huw
Employment - Genentech
Stock and Other Ownership Interests - Genentech
Travel, Accommodations, Expenses - Genentech
 
Carol Elaine O'Hear
Employment - Genentech
Stock and Other Ownership Interests - Roche
 
Yasuhiro Oki
Employment - Genentech; Jazz Pharmaceuticals (I)
 
Iris To
Employment - Genentech
Travel, Accommodations, Expenses - Genentech
 
Catherine S. Magid Diefenbach
Stock and Other Ownership Interests - Gilead Sciences
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Celgene; Genentech/Roche; Janssen; Merck; MorphoSys; Seagen
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); Incyte (Inst); Janssen (Inst); LAM Therapeutics (Inst); MEI Pharma (Inst); Merck (Inst); Millennium (Inst); Roche/Genentech (Inst); Seagen (Inst); Trillium Therapeutics (Inst)